Companies
GMAB
GENMAB A/S
Genmab A/S is a Danish biotech company focused on oncology and cancer therapies, developing monoclonal antibodies and antibody-based drug conjugates for commercial and late-stage programs. The excerpt does not specify individual lead program names or approved products by name, though it references multiple marketed products and product candidates subject to competition from biosimilars and other cancer therapies. Genmab is integrating artificial intelligence and computational approaches into its drug discovery platform for antibody development and precision medicine applications.
$26.52+25.39%1Y
GMAB · daily close · illustrative · 0 catalysts marked
Pipeline
Phase 3PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Phase 2Non Small Cell Lung Cancer Metastatic
Phase 2Cutaneous Melanoma
Phase 2Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID)
Phase 2Metastatic Cutaneous Melanoma (Stage IV)
Phase 2Solid Tumors
Phase 3Follicular Lymphoma (FL)
Phase 2Uterine Cancer
Phase 3Ovarian Cancer
Phase 3Platinum-Sensitive Ovarian Cancer
Phase 3PSOC
Phase 2High Grade Epithelial Ovarian Cancer
Phase 2High Grade Serous Ovarian Cancer
Phase 2Primary Peritoneal Carcinoma
Phase 2Fallopian Tube Cancer
Phase 2Endometrial Cancer
Phase 2Non-Small Cell Lung Cancer
Phase 2Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)
Phase 2Mesothelioma
Phase 2Breast Adenocarcinoma
Phase 2Hormone Receptor-positive/Her2 Negative Breast Cancer
Phase 2Platinum-resistant Ovarian Cancer (PROC)
Phase 2Primary Refractory Ovarian Cancer
Phase 2Breast Cancer
Phase 3Follicular Lymphoma (FL)
Phase 3Diffuse Large B-Cell Lymphoma
Phase 2Non-Hodgkin Lymphoma
Phase 2B-cell Non-Hodgkin Lymphoma
Phase 3PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Phase 3Follicular Lymphoma (FL)
Phase 3Diffuse Large B-Cell Lymphoma
Phase 2B-cell Non-Hodgkin Lymphoma
Phase 2Diffuse Large B-Cell Lymphoma
Phase 2Follicular Lymphoma
Phase 3Follicular Lymphoma (FL)
Phase 2High-grade B-cell Lymphoma
Phase 2Primary Mediastinal Large B Cell Lymphoma
Phase 2Marginal Zone Lymphoma
Phase 2Small Lymphocytic Lymphoma
Phase 2DLBCL
Phase 2FL
Phase 2MCL
Phase 2Indolent B-cell Non-Hodgkin Lymphoma (iNHL)
Phase 2Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)
Phase 2Classic Follicular Lymphoma
Phase 2Non-Hodgkin Lymphoma
Phase 2Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase 2Richter's Syndrome
Phase 2Treatment-naïve High Risk Chronic Lymphocytic Leukemia
Phase 2B-cell Non-Hodgkin Lymphoma
Phase 3Platinum-resistant Ovarian Cancer
Phase 3Diffuse Large B-Cell Lymphoma
Phase 2Malignant Solid Tumor
Phase 2Colorectal Cancer (CRC)
Phase 2Melanoma
Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 2Non-Small Cell Lung Cancer
Phase 3Diffuse Large B-Cell Lymphoma
Phase 2Diffuse Large B-Cell Lymphoma
Phase 2Follicular Lymphoma
Phase 3Follicular Lymphoma (FL)
Phase 2Non-Hodgkin Lymphoma
Phase 2Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase 2Small Lymphocytic Lymphoma
Phase 2Richter's Syndrome
Phase 2Treatment-naïve High Risk Chronic Lymphocytic Leukemia
Phase 2B-cell Non-Hodgkin Lymphoma
Phase 3Follicular Lymphoma (FL)
Phase 3Diffuse Large B-Cell Lymphoma
Phase 3Platinum-resistant Ovarian Cancer
Phase 2Malignant Solid Tumor
Phase 2Colorectal Cancer (CRC)
Phase 2Melanoma
Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 2Non-Small Cell Lung Cancer
Phase 3Platinum-resistant Ovarian Cancer
Phase 3PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
Phase 2Non Small Cell Lung Cancer Metastatic
Phase 2High Grade Epithelial Ovarian Cancer
Phase 2High Grade Serous Ovarian Cancer
Phase 2Primary Peritoneal Carcinoma
Phase 2Fallopian Tube Cancer
Phase 2Endometrial Cancer
Phase 2Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)
Phase 2Mesothelioma
Phase 2Breast Adenocarcinoma
Phase 2Hormone Receptor-positive/Her2 Negative Breast Cancer
Phase 2Platinum-resistant Ovarian Cancer (PROC)
Phase 2Platinum Sensitive Ovarian Cancer (PSOC)
Phase 2Primary Refractory Ovarian Cancer
Phase 2Uterine Cancer
Phase 2Malignant Solid Tumor
Phase 2Colorectal Cancer (CRC)
Phase 2Melanoma
Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 2Breast Cancer
Phase 2Cutaneous Melanoma
Phase 2Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID)
Phase 2Metastatic Cutaneous Melanoma (Stage IV)
Phase 3Follicular Lymphoma (FL)
Phase 3Diffuse Large B-Cell Lymphoma
Phase 2Non-Hodgkin Lymphoma
Phase 2B-cell Non-Hodgkin Lymphoma
Phase 3Platinum-resistant Ovarian Cancer
Phase 3Ovarian Cancer
Phase 3Platinum-Sensitive Ovarian Cancer
Phase 3PSOC
Phase 3Endometrial Cancer
Phase 3Recurrent or Progressive Endometrial Cancer
Phase 2High Grade Epithelial Ovarian Cancer
Phase 2High Grade Serous Ovarian Cancer
Phase 2Primary Peritoneal Carcinoma
Phase 2Fallopian Tube Cancer
Phase 2Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)
Phase 2Mesothelioma
Phase 2Breast Adenocarcinoma
Phase 2Hormone Receptor-positive/Her2 Negative Breast Cancer
Phase 2Primary Refractory Ovarian Cancer
Phase 2Uterine Cancer
Phase 2Breast Cancer
Phase 2Non-Small Cell Lung Cancer
Phase 3Follicular Lymphoma (FL)
Phase 3Diffuse Large B-Cell Lymphoma
Phase 2Non-Hodgkin Lymphoma
Phase 2B-cell Non-Hodgkin Lymphoma
Phase 3Platinum-resistant Ovarian Cancer
Phase 3Follicular Lymphoma (FL)
Phase 3Diffuse Large B-Cell Lymphoma
Phase 2B-cell Non-Hodgkin Lymphoma
Phase 2Malignant Solid Tumor
Phase 2Colorectal Cancer (CRC)
Phase 2Melanoma
Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 2Non-Small Cell Lung Cancer
Phase 2Solid Tumors
Phase 2High Grade Epithelial Ovarian Cancer
Phase 2High Grade Serous Ovarian Cancer
Phase 2Primary Peritoneal Carcinoma
Phase 2Fallopian Tube Cancer
Phase 2Endometrial Cancer
Phase 2Non-Small Cell Lung Cancer
Phase 2Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)
Phase 2Mesothelioma
Phase 2Breast Adenocarcinoma
Phase 2Hormone Receptor-positive/Her2 Negative Breast Cancer
Phase 2Platinum-resistant Ovarian Cancer (PROC)
Phase 2Platinum Sensitive Ovarian Cancer (PSOC)
Phase 2Primary Refractory Ovarian Cancer
Phase 2Uterine Cancer
Phase 2Malignant Solid Tumor
Phase 2Colorectal Cancer (CRC)
Phase 2Melanoma
Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 2Breast Cancer
Phase 2Non-Hodgkin Lymphoma
Phase 2Malignant Solid Tumor
Phase 2Colorectal Cancer (CRC)
Phase 2Melanoma
Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 2Non-Small Cell Lung Cancer
Phase 2Non-Hodgkin Lymphoma
Phase 2Diffuse Large B-Cell Lymphoma
Phase 2High-grade B-cell Lymphoma
Phase 2Primary Mediastinal Large B Cell Lymphoma
Phase 2Follicular Lymphoma
Phase 2Marginal Zone Lymphoma
Phase 2Small Lymphocytic Lymphoma
Phase 2Diffuse Large B-Cell Lymphoma
Phase 2High-grade B-cell Lymphoma
Phase 2Primary Mediastinal Large B Cell Lymphoma
Phase 2Follicular Lymphoma
Phase 2Marginal Zone Lymphoma
Phase 2Small Lymphocytic Lymphoma
Phase 2Diffuse Large B-Cell Lymphoma
Phase 2Follicular Lymphoma
Phase 2High-grade B-cell Lymphoma
Phase 2Primary Mediastinal Large B Cell Lymphoma
Phase 2Marginal Zone Lymphoma
Phase 2Small Lymphocytic Lymphoma
Phase 2Malignant Solid Tumor
Phase 2Colorectal Cancer (CRC)
Phase 2Melanoma
Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 2Non-Small Cell Lung Cancer
Phase 2Non-Hodgkin Lymphoma
Phase 2Malignant Solid Tumor
Phase 2Colorectal Cancer (CRC)
Phase 2Melanoma
Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 2Non-Small Cell Lung Cancer
Phase 2Malignant Solid Tumor
Phase 2Colorectal Cancer (CRC)
Phase 2Melanoma
Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 2Non-Small Cell Lung Cancer
Phase 2Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase 2Small Lymphocytic Lymphoma
Phase 2Richter's Syndrome
Phase 2Treatment-naïve High Risk Chronic Lymphocytic Leukemia
Phase 2Non-Hodgkin Lymphoma
Phase 2Diffuse Large B-Cell Lymphoma
Phase 2Follicular Lymphoma
Phase 2High-grade B-cell Lymphoma
Phase 2Primary Mediastinal Large B Cell Lymphoma
Phase 2Marginal Zone Lymphoma
Phase 2Small Lymphocytic Lymphoma
Phase 2Diffuse Large B-Cell Lymphoma
Phase 2Follicular Lymphoma
Phase 2High-grade B-cell Lymphoma
Phase 2Primary Mediastinal Large B Cell Lymphoma
Phase 2Marginal Zone Lymphoma
Phase 2Small Lymphocytic Lymphoma
Phase 2Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase 2Richter's Syndrome
Phase 2Treatment-naïve High Risk Chronic Lymphocytic Leukemia
Phase 2Diffuse Large B-Cell Lymphoma
Phase 2Follicular Lymphoma
Phase 2Diffuse Large B-Cell Lymphoma
Phase 2Follicular Lymphoma
Phase 2Diffuse Large B-Cell Lymphoma
Phase 2Follicular Lymphoma
Phase 2Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase 2Small Lymphocytic Lymphoma
Phase 2Richter's Syndrome
Phase 2Treatment-naïve High Risk Chronic Lymphocytic Leukemia
Catalyst Calendar
No catalyst events on record for yet. Check back after the next daily ingest.